Overview

De-escalation of Ticagrelor in Post PPCI

Status:
Not yet recruiting

Trial end date:
2024-05-01

Target enrollment:
0

Participant gender:
All

Summary

Primary objective: to evaluate the efficacy and safety of De-escalation to lower dose Ticagrelor (60 mg BID) plus Aspirin (75 mg OD) versus continuation of standard dose Ticagrelor (90 mg BID) plus Aspirin (75 mg OD), 1 month after primary PCI for STEMI, in diabetic patients. Secondary objectives: To compare tolerability and discontinuation of Ticagrelor in both doses. To compare the 1ry safety & efficacy endpoints in subgroups with different thrombotic/ischemic risk

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Ticagrelor

Criteria

Inclusion Criteria:

Diabetes Mellitus. Acute STEMI. Able to swallow tablets.

Exclusion Criteria:

Patients presenting with stent thrombosis. Hypersensitivity to ticagrelor and/or aspirin.
Active bleeding. ARC-high bleeding risk status1. 2nd or 3rd degree AV block. Previous stent
thrombosis on treatment with ticagrelor. Pregnancy or lactation.